Abstract
Background and Objectives
Chiglitazar is a novel configuration-restricted non-thiazolidinedione peroxisome proliferator-activated receptor pan-agonist currently in the Phase III clinical development stage for type 2 diabetes mellitus patients. The objective of this Phase I study was to evaluate the pharmacokinetics, safety and tolerability of single and multiple doses of chiglitazar tablets taken orally and the effect of food on its pharmacokinetics in healthy Chinese subjects.
Methods
A single-centre, open-label, randomised, two-stage Phase I study was carried out. In the first-stage study, we evaluated a single dose of 8, 16, or 32 mg, and multiple doses of 16 mg, taken once daily for 9 days. The effect of food consumption was also studied in this stage. In the second-stage study, a greater range of single doses (24, 48 or 72 mg) were further evaluated. Pharmacokinetics, safety and tolerability profiles were assessed at each study stage.
Results
After a single oral dose of chiglitazar, at doses ranging from 8 to 72 mg, the maximum plasma concentration (Cmax) and area under the concentration–time curve (AUC) were proportionally increased (165–1599 ng/mL for the mean Cmax and 1356–12,584 ng·h/mL for the mean AUC0−t), with low inter-subject variability. There were no significant changes in the mean terminal phase half-life (t1/2), which ranged from 9.0 to 11.9 h, and the clearance and volume of distribution were similar for all evaluated doses. The results from the examination of multiple dose of 16 mg once daily for nine consecutive days showed that a steady-state condition was achieved by Day 6. There was no apparent accumulation of chiglitazar observed at Day 9, as compared with the first administration. While food increased the AUC0−t of chiglitazar by about 13%, there were no effects on other parameters, including Cmax, Tmax and t1/2. There were no serious or severe adverse events observed in the single- or multiple-dose studies.
Conclusions
Chiglitazar tablets showed a good dose-dependent linear pharmacokinetic profile in the dose range of 8–72 mg. There was no accumulation after multiple daily administration of chiglitazar at a dose of 16 mg. High-fat/calorie food increased the absorption of the drug, but there were no significant changes in exposure and other pharmacokinetic parameters. Chiglitazar was safe and well tolerated in healthy Chinese subjects at the dose levels and administration regimens evaluated.
Similar content being viewed by others
References
Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al. IDF diabetes atlas, sixth edition. International Diabetes Federation. 2013.
Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 1900;365(9467):1333–46.
Brunzell JD, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg. Diabetes Care. 2005;28(12):2985–6.
Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem. 1998;273(49):32679.
Elasy TA, Griffin M. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto. Pediatr Emerg Care. 2008;108(23):344–5.
Ajay C, Julio R, Andres DG, Luigi M, Priscilla H, Mcgill JB, et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes. 2012;28(3):258–67.
Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract. 2004;58(9):833–7.
Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol. 2007;27(11):2428.
Calvo E, Reddy G, Boni V, García-Cañamaque L, Song T, Tjornelund J, et al. Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies. Invest New Drugs. 2016;34(2):193–201.
He BK, Ning ZQ, Li ZB, Shan S, Pan DS, Ko BC, et al. In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist. PPAR Res. 2012;2012(10):546548.
Abbott BD. Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol. 2009;27(3):246–57.
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405(6785):421–4.
Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, et al. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015;3:3.
Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010;30(5):894–9.
Li PP, Shan S, Chen YT, Ning ZQ, Sun SJ, Liu Q, et al. The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br J Pharmacol. 2006;148(5):610–8.
Patel MR, Kansagra KA, Parikh DP, Parmar DV, Patel HB, Soni MM, et al. Effect of food on the pharmacokinetics of saroglitazar magnesium, a novel dual PPARαγ agonist, healthy adult subjects. Clin Drug Investig. 2017;38(S2):1–9.
Rajendra HJ, Kevinkumar K, Mukul RJ, Harilal P. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects. Clin Drug Investig. 2013;33(11):809–16.
Risérus USD, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men [J]. Diabetes. 2008;57(2):332.
Lu XP, Li ZB, Ning ZQ, inventors; Preparation of amorphous salts of Chiglitazar for treatment of metabolic syndrome. USA patent CN105801468A2016.
Pan DSWW, Liu NS, et al. Chiglitazar preferentially regulates gene expression via configuration-restricted binding and phosphorylation inhibition of PPAR. Ppar Res. 2017;2017(7):1–16.
Drug clinical trial registration platform. http://www.chinadrugtrials.org.cn [CTR20131996; CTR20140262]. Accessed 1 Mar 2019.
Meng Z. Preclinical pharmacokinetics of chiglitazar. Drug Metab Rev. 2006;38:71–2.
Chu NN, Li XN, Chen WL, Xu HR. Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatography-tandem mass spectrometry. Pharm Die. 2007;62(11):825–9.
Liao CZ, Deng T, Shang S, Pan DS, Zhi-Bin LI, Ning ZQ, et al. Current strategies in research of anti-diabetics by employment of PPAR (peroxisome proliferator-activated receptor) as a target. Chin New Drugs J. 2003.
Lan YK, Bao-Shun MA, Yin ZH, Liao CZ, Shan S, Zhi-Liang LI, et al. Synthesis of chiglitazar, a new insulin sensitizer. Chin New Drugs J. 2004;13(8):718–20.
US Food & Drug Administration Guidance. 2018. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM616325.pdf. Accessed 1 Mar 2019.
Acknowledgements
The authors wish to thank the participants, study investigators, coordinators and study site personnel who contributed to this study.
Author information
Authors and Affiliations
Contributions
All authors participated in the design of the study and contributed to acquisition, analysis and interpretation of data. The sponsor, Chipscreen Biosciences Co., Ltd, provided for editorial and medical writing support. All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
Jin-Wen Zhang and Zhi-Qiang Ning are employees of Shenzhen Chipscreen Biosciences Co., Ltd. Hong-Rong Xu, Wei-Li Chen and Xue-Ning Li are employees of ZhongShan Hospital, Fudan University, and declare that they have no conflicts of interest in this study.
Funding
The study was supported by the following project Grants: (1) “Research on the pharmacokinetics of chiglitazar tablet, a new drug in category 1.1 for diabetes” (No. CXZZ20151013171242907) from the Shenzhen Science and Technology Innovation Committee; (2) a National Science and Technology “863” Project (No. 2002AA2Z3146); and (3) a National Science and Technology Significant Project in the category “New Drug Initiative” (2008ZX09101-002).
Ethical Approval
The study protocol was approved by the independent ethics committee and the institutional review board of the ZhongShan Hospital, Fudan University. The study was performed in accordance with the Declaration of Helsinki, the Good Clinical Practice Guidelines and local laws.
Informed Consent
Written informed consent was obtained from all individual participants prior to their enrolment.
Rights and permissions
About this article
Cite this article
Xu, HR., Zhang, JW., Chen, Wl. et al. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study. Clin Drug Investig 39, 553–563 (2019). https://doi.org/10.1007/s40261-019-00779-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-019-00779-4